Voyager Therapeutics (VYGR) Enterprise Value (2016 - 2025)
Voyager Therapeutics (VYGR) has disclosed Enterprise Value for 11 consecutive years, with -$196.4 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 26.34% to -$196.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$196.4 million through Dec 2025, up 26.34% year-over-year, with the annual reading at -$196.4 million for FY2025, 26.34% up from the prior year.
- Enterprise Value hit -$196.4 million in Q4 2025 for Voyager Therapeutics, up from -$208.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$118.8 million in Q4 2022 to a low of -$399.6 million in Q1 2024.
- Historically, Enterprise Value has averaged -$219.7 million across 5 years, with a median of -$212.3 million in 2025.
- Biggest five-year swings in Enterprise Value: crashed 94.26% in 2023 and later skyrocketed 41.89% in 2025.
- Year by year, Enterprise Value stood at -$132.5 million in 2021, then increased by 10.33% to -$118.8 million in 2022, then plummeted by 94.26% to -$230.9 million in 2023, then fell by 15.51% to -$266.7 million in 2024, then rose by 26.34% to -$196.4 million in 2025.
- Business Quant data shows Enterprise Value for VYGR at -$196.4 million in Q4 2025, -$208.9 million in Q3 2025, and -$215.6 million in Q2 2025.